Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience

被引：0
|
作者：
Olgun, N. [1 ]
Cecen, R. E. [1 ]
Ince, D. [1 ]
Onal, A. [1 ]
Baysal, B. [2 ]
Akyol, S. [1 ]
Ozdogan, O. [3 ]
Guleryuz, H. [4 ]
Aktas, S. [1 ]
Ozer, E. [5 ]
机构：
[1] Dokuz Eylul Univ, Inst Oncol, Izmir, Turkey
[2] Marmara Univ, Educ & Res Hosp, Pediat Hematol & Oncol, Istanbul, Turkey
[3] Dokuz Eylul Univ, Nucl Med, Izmir, Turkey
[4] Dokuz Eylul Univ, Radiodiagnost, Izmir, Turkey
[5] Dokuz Eylul Univ, Pathol, Izmir, Turkey
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PV0129
引用
收藏
页码：S215 / S215
页数：1
相关论文
共 50 条
  • [41] Allografting in relapsed/refractory Hodgkin's lymphoma, a single-centre experience
    Festuccia, M.
    Passera, R.
    Giaccone, L.
    Locatelli, F.
    Busca, A.
    D'Ardia, S.
    Allione, B.
    Boccadoro, M.
    Vitolo, U.
    Falda, M.
    Bruno, B.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S443 - S444
  • [42] TREATMENT OUTCOME OF HIGH-DOSE CHEMOTHERAPY PLUS STEM CELL RESCUE IN HIGH-RISK NEUROBLASTOMA IN THAILAND
    Suwannaying, Kunanya
    Techavichit, Piti
    Patcharee, Patcharee
    Laoaroon, Napat
    Narkbunnam, Nattee
    Sanpakit, Kleebsabai
    Chiengthong, Kanhatai
    Chotsampancharoen, Thirachit
    Sathitsamitphong, Lalita
    Santong, Chalongpon
    Seksarn, Panya
    Hongeng, Suradej
    Wiangnon, Surapon
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S599 - S599
  • [43] CLOFARABINE IN RELAPSED-REFRACTORY ACUTE MYELOGENOUS LEUKEMIA: A SINGLE CENTRE EXPERIENCE
    Scappini, B.
    Gianfaldoni, G.
    Armenio, M.
    Mannelli, F.
    Cutini, I.
    Piccini, M.
    Biagiotti, C.
    Fanci, R.
    Di Gioia, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 680 - 680
  • [44] Allogeneic transplantation for patients with high-risk or refractory neuroblastoma.
    Driscoll, T. A.
    Martin, P. L.
    Moffet, J.
    Daniel, M.
    Page, K.
    Parikh, S.
    Prasad, V.
    Szabolcs, P.
    Kurtzberg, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
  • [46] High-risk cytogenetic abnormalities in acute myeloid leukaemia - single centre experience
    Kamran, S.
    Mir, A.
    Ahmad, K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 192 - 193
  • [47] P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma
    Atkinson, Caroline
    Tactacan, Carole
    Kamili, Alvin
    Saletta, Federica
    Gana, Christine
    Eden, Georgina
    Mayoh, Chelsea
    Lock, Richard
    Norris, Murray
    Haber, Michelle
    Gifford, Andrew
    Trahair, Toby
    Fletcher, Jamie
    CANCER RESEARCH, 2020, 80 (14) : 61 - 61
  • [48] Unrelated cord blood transplantation for children with high-risk or relapsed neuroblastoma
    Takahashi, Y.
    Matsumoto, K.
    Fujisaki, H.
    Iwasaki, F.
    Hashii, Y.
    Nakamura, K.
    Sugita, K.
    Yabe, H.
    Kato, K.
    Takanashi, M.
    Atsuta, Y.
    Inoue, M.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S47 - S47
  • [49] Survival and palliative care decision making in high-risk neuroblastoma patients with refractory or relapsed disease: Experience from two paediatric oncology centres in the UK
    Ramanujachar, Ramya
    Marshall, Lynley
    Delany, Judith
    Brock, Penelope
    Pritchard-Jones, Kathy
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 568 - 568
  • [50] Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution
    S Proust-Houdemont
    C Pasqualini
    P Blanchard
    C Dufour
    E Benhamou
    G Goma
    M Semeraro
    M-A Raquin
    O Hartmann
    D Valteau-Couanet
    Bone Marrow Transplantation, 2016, 51 : 1076 - 1081
12345